In its February 2024 meeting, the European Medicines Agency's (EMA's) Committee for Medicinal Products for Human Use has granted marketing authorizations for Pyzchiva (ustekinumab) for the treatment ...
Four Phase 3 ICONIC trials assessed the oral IL-23 receptor antagonist icotrokinra in more than 2,500 patients with plaque ...
FDA approved roflumilast topical foam 0.3% for plaque psoriasis, highlighting the role of PDE-4 inhibition and offering a steroid-free option for hair-bearing areas. Oral roflumilast showed potential ...
From visible symptoms and painful flares to unexpected lessons in self-care, three people share the realities of living with ...
Having completed their phase 1b clinical trial in psoriasis, with outstanding results, SFA Therapeutics, Inc. is now positioning itself for the commercial development of SFA-002D, a drug that has the ...
Psoriasis is often associated with the skin, but doctors say the autoimmune disease can also affect the joints and lead to permanent damage if psoriatic arthritis is not treated early.
Psoriasis is a chronic, inflammatory skin condition, but its effects go well beyond the skin. While its often recognized for its itchy, scaly patches, experts believe that the root causes of psoriasis ...
Psoriatic arthritis (PsA) is a chronic inflammatory joint disease, usually linked to psoriasis, caused by a combination of ...
For celebrities who are constantly in the public eye, anything unpredictable when it comes to their appearance can bring added stress. That means that having a diagnosis of psoriasis — a condition ...
Italian researchers reporting in the journal Cancers found a 32% increase in the odds for cancer in the first year after a diagnosis for an autoimmune disease such as lupus, rheumatoid arthritis or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results